Eintrag weiter verarbeiten
Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia
Gespeichert in:
| Zeitschriftentitel: | Hematology |
|---|---|
| Personen und Körperschaften: | , |
| In: | Hematology, 2013, 2013, 1, S. 324-330 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Hematology
|
| Schlagwörter: |
| author_facet |
Schlenk, Richard F. Döhner, Hartmut Schlenk, Richard F. Döhner, Hartmut |
|---|---|
| author |
Schlenk, Richard F. Döhner, Hartmut |
| spellingShingle |
Schlenk, Richard F. Döhner, Hartmut Hematology Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia Hematology |
| author_sort |
schlenk, richard f. |
| spelling |
Schlenk, Richard F. Döhner, Hartmut 1520-4391 1520-4383 American Society of Hematology Hematology http://dx.doi.org/10.1182/asheducation-2013.1.324 <jats:title>Abstract</jats:title> <jats:p>In recent years, research in genomics has resulted in the rapid uncovering of the molecular pathogenesis of acute myeloid leukemia (AML). The identification of the genetic determinants of response to standard—but also to experimental—treatment is increasingly used for patient counseling, to guide clinical decision making, and for resource-efficient care provision at diagnosis, during consolidation treatment and follow-up, and after relapse. Gene mutations now allow us to explore the enormous diversity among cytogenetically defined subsets of AML, in particular the large subset of cytogenetically normal AML. Nonetheless, there are several challenges in evaluating the prognostic value of a specific mutation in the concert of the various concurrent mutations and determining the relative prognostic value of the genetic profile during the disease course. In particular, changes in the genetic profile in relapse compared with that at diagnosis will increasingly affect the treatment strategy at relapse, but also will give us the possibility of learning which treatment strategy during frontline therapy is best to prevent them.</jats:p> Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia Hematology |
| doi_str_mv |
10.1182/asheducation-2013.1.324 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9hc2hlZHVjYXRpb24tMjAxMy4xLjMyNA |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9hc2hlZHVjYXRpb24tMjAxMy4xLjMyNA |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-D161 DE-Zwi2 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
American Society of Hematology, 2013 |
| imprint_str_mv |
American Society of Hematology, 2013 |
| issn |
1520-4391 1520-4383 |
| issn_str_mv |
1520-4391 1520-4383 |
| language |
English |
| mega_collection |
American Society of Hematology (CrossRef) |
| match_str |
schlenk2013genomicapplicationsintheclinicuseintreatmentparadigmofacutemyeloidleukemia |
| publishDateSort |
2013 |
| publisher |
American Society of Hematology |
| recordtype |
ai |
| record_format |
ai |
| series |
Hematology |
| source_id |
49 |
| title |
Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia |
| title_unstemmed |
Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia |
| title_full |
Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia |
| title_fullStr |
Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia |
| title_full_unstemmed |
Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia |
| title_short |
Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia |
| title_sort |
genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia |
| topic |
Hematology |
| url |
http://dx.doi.org/10.1182/asheducation-2013.1.324 |
| publishDate |
2013 |
| physical |
324-330 |
| description |
<jats:title>Abstract</jats:title>
<jats:p>In recent years, research in genomics has resulted in the rapid uncovering of the molecular pathogenesis of acute myeloid leukemia (AML). The identification of the genetic determinants of response to standard—but also to experimental—treatment is increasingly used for patient counseling, to guide clinical decision making, and for resource-efficient care provision at diagnosis, during consolidation treatment and follow-up, and after relapse. Gene mutations now allow us to explore the enormous diversity among cytogenetically defined subsets of AML, in particular the large subset of cytogenetically normal AML. Nonetheless, there are several challenges in evaluating the prognostic value of a specific mutation in the concert of the various concurrent mutations and determining the relative prognostic value of the genetic profile during the disease course. In particular, changes in the genetic profile in relapse compared with that at diagnosis will increasingly affect the treatment strategy at relapse, but also will give us the possibility of learning which treatment strategy during frontline therapy is best to prevent them.</jats:p> |
| container_issue |
1 |
| container_start_page |
324 |
| container_title |
Hematology |
| container_volume |
2013 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792334690178301965 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T14:32:40.08Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Genomic+applications+in+the+clinic%3A+use+in+treatment+paradigm+of+acute+myeloid+leukemia&rft.date=2013-12-06&genre=article&issn=1520-4383&volume=2013&issue=1&spage=324&epage=330&pages=324-330&jtitle=Hematology&atitle=Genomic+applications+in+the+clinic%3A+use+in+treatment+paradigm+of+acute+myeloid+leukemia&aulast=D%C3%B6hner&aufirst=Hartmut&rft_id=info%3Adoi%2F10.1182%2Fasheducation-2013.1.324&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792334690178301965 |
| author | Schlenk, Richard F., Döhner, Hartmut |
| author_facet | Schlenk, Richard F., Döhner, Hartmut, Schlenk, Richard F., Döhner, Hartmut |
| author_sort | schlenk, richard f. |
| container_issue | 1 |
| container_start_page | 324 |
| container_title | Hematology |
| container_volume | 2013 |
| description | <jats:title>Abstract</jats:title> <jats:p>In recent years, research in genomics has resulted in the rapid uncovering of the molecular pathogenesis of acute myeloid leukemia (AML). The identification of the genetic determinants of response to standard—but also to experimental—treatment is increasingly used for patient counseling, to guide clinical decision making, and for resource-efficient care provision at diagnosis, during consolidation treatment and follow-up, and after relapse. Gene mutations now allow us to explore the enormous diversity among cytogenetically defined subsets of AML, in particular the large subset of cytogenetically normal AML. Nonetheless, there are several challenges in evaluating the prognostic value of a specific mutation in the concert of the various concurrent mutations and determining the relative prognostic value of the genetic profile during the disease course. In particular, changes in the genetic profile in relapse compared with that at diagnosis will increasingly affect the treatment strategy at relapse, but also will give us the possibility of learning which treatment strategy during frontline therapy is best to prevent them.</jats:p> |
| doi_str_mv | 10.1182/asheducation-2013.1.324 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9hc2hlZHVjYXRpb24tMjAxMy4xLjMyNA |
| imprint | American Society of Hematology, 2013 |
| imprint_str_mv | American Society of Hematology, 2013 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-D161, DE-Zwi2, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 1520-4391, 1520-4383 |
| issn_str_mv | 1520-4391, 1520-4383 |
| language | English |
| last_indexed | 2024-03-01T14:32:40.08Z |
| match_str | schlenk2013genomicapplicationsintheclinicuseintreatmentparadigmofacutemyeloidleukemia |
| mega_collection | American Society of Hematology (CrossRef) |
| physical | 324-330 |
| publishDate | 2013 |
| publishDateSort | 2013 |
| publisher | American Society of Hematology |
| record_format | ai |
| recordtype | ai |
| series | Hematology |
| source_id | 49 |
| spelling | Schlenk, Richard F. Döhner, Hartmut 1520-4391 1520-4383 American Society of Hematology Hematology http://dx.doi.org/10.1182/asheducation-2013.1.324 <jats:title>Abstract</jats:title> <jats:p>In recent years, research in genomics has resulted in the rapid uncovering of the molecular pathogenesis of acute myeloid leukemia (AML). The identification of the genetic determinants of response to standard—but also to experimental—treatment is increasingly used for patient counseling, to guide clinical decision making, and for resource-efficient care provision at diagnosis, during consolidation treatment and follow-up, and after relapse. Gene mutations now allow us to explore the enormous diversity among cytogenetically defined subsets of AML, in particular the large subset of cytogenetically normal AML. Nonetheless, there are several challenges in evaluating the prognostic value of a specific mutation in the concert of the various concurrent mutations and determining the relative prognostic value of the genetic profile during the disease course. In particular, changes in the genetic profile in relapse compared with that at diagnosis will increasingly affect the treatment strategy at relapse, but also will give us the possibility of learning which treatment strategy during frontline therapy is best to prevent them.</jats:p> Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia Hematology |
| spellingShingle | Schlenk, Richard F., Döhner, Hartmut, Hematology, Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia, Hematology |
| title | Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia |
| title_full | Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia |
| title_fullStr | Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia |
| title_full_unstemmed | Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia |
| title_short | Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia |
| title_sort | genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia |
| title_unstemmed | Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia |
| topic | Hematology |
| url | http://dx.doi.org/10.1182/asheducation-2013.1.324 |